NEUROCRINE BIOSCIENCES INC— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$4.63B
↑+24.5% +$913Mvs FY2024
Total Liabilities
$1.38B
↑+22.1% +$249Mvs FY2024
Equity
$3.25B
↑+25.6% +$663Mvs FY2024
Cash
$713M
↑+206.0% +$480Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $4.63B | $3.72B |
| Current Assets | $2.52B | $1.72B |
| Cash | $713M | $233M |
| ST Investments | $0 | $0 |
| Receivables | $687M | $479M |
| Inventory | $69M | $57M |
| Other Current | $1.05B | $955M |
| Non-Current Assets | $2.11B | $1.99B |
| PPE | $90M | $83M |
| Goodwill | $0 | $6M |
| Intangibles | $0 | $37M |
| Investments | $0 | $0 |
| Other Non-Current | $2.02B | $1.87B |
| Total Liab+Eq | $4.63B | $3.72B |
| Current Liab. | $743M | $508M |
| Accounts Payable | $0 | $0 |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $743M | $508M |
| Non-Current Liab. | $635M | $621M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $635M | $621M |
| Equity | $3.25B | $2.59B |
| Retained Earnings | $448M | $29M |
| Other Equity | $2.81B | $2.56B |
QuarterCharts · SEC EDGAR data · NBIX · Comparing FY2025 vs FY2024